212 related articles for article (PubMed ID: 3544373)
1. OKT3 treatment of steroid-resistant renal allograft rejection.
Thistlethwaite JR; Gaber AO; Haag BW; Aronson AJ; Broelsch CE; Stuart JK; Stuart FP
Transplantation; 1987 Feb; 43(2):176-84. PubMed ID: 3544373
[TBL] [Abstract][Full Text] [Related]
2. Use of a brief steroid trial before initiating OKT3 therapy for renal allograft rejection.
Thistlethwaite JR; Stuart JK; Mayes JT; Gaber AO; Stuart FP
Am J Kidney Dis; 1988 Feb; 11(2):94-8. PubMed ID: 3277413
[TBL] [Abstract][Full Text] [Related]
3. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function.
Benvenisty AI; Cohen D; Stegall MD; Hardy MA
Transplantation; 1990 Feb; 49(2):321-7. PubMed ID: 2137654
[TBL] [Abstract][Full Text] [Related]
4. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection.
Thistlethwaite JR; Cosimi AB; Delmonico FL; Rubin RH; Talkoff-Rubin N; Nelson PW; Fang L; Russell PS
Transplantation; 1984 Dec; 38(6):695-701. PubMed ID: 6390834
[TBL] [Abstract][Full Text] [Related]
5. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
[TBL] [Abstract][Full Text] [Related]
6. Experience with OKT3 in vascularized pancreas transplantation.
Sollinger HW; Stratta RJ
Am J Kidney Dis; 1988 Feb; 11(2):145-8. PubMed ID: 3277405
[TBL] [Abstract][Full Text] [Related]
7. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation.
D'Alessandro AM; Pirsch JD; Stratta RJ; Sollinger HW; Kalayoglu M; Maki DG; Belzer FO
Transplantation; 1989 Feb; 47(2):297-300. PubMed ID: 2493176
[TBL] [Abstract][Full Text] [Related]
8. Delayed response to orthoclone OKT3 treatment for renal allograft rejection resistant to steroid and antilymphocyte globulin.
Oh CS; Sollinger HW; Stratta RJ; Kalayoglu M; Belzer FO
Transplantation; 1988 Jan; 45(1):65-7. PubMed ID: 3276065
[TBL] [Abstract][Full Text] [Related]
9. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
[TBL] [Abstract][Full Text] [Related]
10. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection.
Midtvedt K; Tafjord AB; Hartmann A; Eide TC; Holdaas H; Nordal KP; Draganov B; Sødal G; Leivestad T; Fauchald P
Transplantation; 1996 Jul; 62(1):38-42. PubMed ID: 8693541
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic use of OKT3 monoclonal antibody for acute renal allograft rejection.
Norman DJ; Shield CF; Barry JM; Henell K; Funnell MB; Lemon J
Nephron; 1987; 46 Suppl 1():41-7. PubMed ID: 3306424
[TBL] [Abstract][Full Text] [Related]
12. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation.
Norman DJ; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Dehlinger J; Wu SC; Van Horn A; Haverty TP
Transplantation; 1993 Jan; 55(1):44-50. PubMed ID: 8420063
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients.
Schulak JA; Mayes JT; Moritz CE; Hricik DE
Transplantation; 1990 Feb; 49(2):327-32. PubMed ID: 2407003
[TBL] [Abstract][Full Text] [Related]
14. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
[TBL] [Abstract][Full Text] [Related]
15. A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection.
Deierhoi MH; Barber WH; Curtis JJ; Julian BA; Luke RG; Hudson S; Barger BO; Diethelm AG
Am J Kidney Dis; 1988 Feb; 11(2):86-9. PubMed ID: 3277412
[TBL] [Abstract][Full Text] [Related]
16. OKT3 rescue therapy in pancreas-allograft rejection.
Stratta RJ; Sollinger HW; D'Alessandro AM; Pirsch JD; Kalayoglu M; Belzer FO
Diabetes; 1989 Jan; 38 Suppl 1():74-8. PubMed ID: 2521330
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
Waid TH; Lucas BA; Thompson JS; Brown SA; Munch L; Prebeck RJ; Jezek D
Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095
[TBL] [Abstract][Full Text] [Related]
18. Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation.
Millis JM; McDiarmid SV; Hiatt JR; Brems JJ; Colonna JO; Klein AS; Ashizawa T; Hart J; Lewin K; Goldstein LI
Transplantation; 1989 Jan; 47(1):82-8. PubMed ID: 2521409
[TBL] [Abstract][Full Text] [Related]
19. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection.
Norman DJ; Shield CF; Barry J; Bennett WM; Henell K; Kimball J; Funnell B; Hubert B
Am J Kidney Dis; 1988 Feb; 11(2):107-10. PubMed ID: 3277400
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
